Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas John

Showing results (341-350 of 354) with videos related to

Pageof 36
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2025
Advances in Lung Cancer Basic and Translational Research in 2025 - Overview and Perspectives Focusing on NSCLCCeline Mascaux, Triparna Sen, Montse Sanchez-Cespedes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2023
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based ChemotherapyHelena A Yu, Yasushi Goto, Hidetoshi Hayashi, et al.
JTO Clinical and Research Reports|January 29, 2025
Durvalumab, Tremelimumab, and Platinum Chemotherapy in <i>EGFR</i> Mutation-Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)Chee Khoon Lee, Bin-Chi Liao, Shalini Subramaniam, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 28, 2026
Consensus statement on ctDNA minimal residual disease (MRD) testing in early-stage NSCLC - A Delphi study by the Asian Thoracic Oncology Research Group (ATORG)Aaron C Tan, Bin-Chi Liao, Molly Li, et al.
The Medical Journal of Australia|June 28, 2026
Treatment and Survival Outcomes for Indigenous and Non-Indigenous Australians Within the Victorian Lung Cancer Registry: A Retrospective Cross-Sectional Cohort StudyMelanie Wong, Mike Lloyd, Jessie Zeng, et al.
Journal of Cancer Policy|November 26, 2023
A tailored approach to horizon scanning for cancer medicinesJennifer A Soon, Yat Hang To, Marliese Alexander, et al.
Cell Reports. Medicine|December 28, 2024
Coupling of response biomarkers between tumor and peripheral blood in patients undergoing chemoimmunotherapyWee Loong Chin, Alistair M Cook, Jonathan Chee, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 7, 2025
Common inherited loss-of-function mutations in the innate sensor NOD2 contribute to exceptional immune response to cancer immunotherapyMegan B Barnet, Katherine J L Jackson, Etienne Masle-Farquhar, et al.
The Lancet. Oncology|December 16, 2019
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trialsAlexander Drilon, Salvatore Siena, Rafal Dziadziuszko, et al.
The Lancet. Oncology|December 16, 2019
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trialsRobert C Doebele, Alexander Drilon, Luis Paz-Ares, et al.
Pageof 36

Showing results (341-350 of 354) with videos related to

Sort By:
Pageof 36
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2025
Advances in Lung Cancer Basic and Translational Research in 2025 - Overview and Perspectives Focusing on NSCLCCeline Mascaux, Triparna Sen, Montse Sanchez-Cespedes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2023
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based ChemotherapyHelena A Yu, Yasushi Goto, Hidetoshi Hayashi, et al.
JTO Clinical and Research Reports|January 29, 2025
Durvalumab, Tremelimumab, and Platinum Chemotherapy in <i>EGFR</i> Mutation-Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)Chee Khoon Lee, Bin-Chi Liao, Shalini Subramaniam, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 28, 2026
Consensus statement on ctDNA minimal residual disease (MRD) testing in early-stage NSCLC - A Delphi study by the Asian Thoracic Oncology Research Group (ATORG)Aaron C Tan, Bin-Chi Liao, Molly Li, et al.
The Medical Journal of Australia|June 28, 2026
Treatment and Survival Outcomes for Indigenous and Non-Indigenous Australians Within the Victorian Lung Cancer Registry: A Retrospective Cross-Sectional Cohort StudyMelanie Wong, Mike Lloyd, Jessie Zeng, et al.
Journal of Cancer Policy|November 26, 2023
A tailored approach to horizon scanning for cancer medicinesJennifer A Soon, Yat Hang To, Marliese Alexander, et al.
Cell Reports. Medicine|December 28, 2024
Coupling of response biomarkers between tumor and peripheral blood in patients undergoing chemoimmunotherapyWee Loong Chin, Alistair M Cook, Jonathan Chee, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 7, 2025
Common inherited loss-of-function mutations in the innate sensor NOD2 contribute to exceptional immune response to cancer immunotherapyMegan B Barnet, Katherine J L Jackson, Etienne Masle-Farquhar, et al.
The Lancet. Oncology|December 16, 2019
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trialsAlexander Drilon, Salvatore Siena, Rafal Dziadziuszko, et al.
The Lancet. Oncology|December 16, 2019
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trialsRobert C Doebele, Alexander Drilon, Luis Paz-Ares, et al.
Pageof 36